J&J Enters LAA Closure Market In Earnest With Coherex Buy
This article was originally published in Clinica
Johnson & Johnson's Biosense Webster unit already is the exclusive distributor of Coherex Medical Inc.'s WaveCrest left atrial appendage occlusion system outside of the US, but the heart-rhythm device business now says it is acquiring the Coherex outright, expanding its commitment to the LAA closure space for reducing stroke in atrial fibrillation patients.
You may also be interested in...
HRS 2017: EBR's Leadless CRT Feasibility; Watchman Registry Data; A Novel AF Ablation Catheter From BW; And More Medtronic CRT Data
Results from "real-world" registries of established devices, along with encouraging early results from novel devices were among the highlights of Heart Rhythm 2017, the annual scientific sessions of the Heart Rhythm Society, held in Chicago May 10-13.
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.